Seoul Pharma Co., Ltd (KOSDAQ: 018680)
South Korea
· Delayed Price · Currency is KRW 3,815.00
-10.00 (-0.26%)
Oct 2, 2024, 9:00 AM KST
Seoul Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | 2006 - 2005 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '12 Sep 30, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | Dec '07 Dec 31, 2007 | 2006 - 2005 |
| Net Income | 1,053 | 1,333 | 1,413 | 1,181 | 542.04 | -2,510 | Upgrade
|
| Depreciation & Amortization | 344.43 | - | - | 1,065 | 1,021 | 925.08 | Upgrade
|
| Loss (Gain) From Sale of Assets | 217.2 | - | - | -11.75 | -67.6 | -8.53 | Upgrade
|
| Stock-Based Compensation | 28.19 | - | - | 87.51 | 121.78 | 121.45 | Upgrade
|
| Provision & Write-off of Bad Debts | -371.03 | - | - | 489.99 | 230.05 | 24.1 | Upgrade
|
| Other Operating Activities | 2,249 | 2,395 | 721.43 | -1.31 | 581.41 | 587.12 | Upgrade
|
| Change in Accounts Receivable | -3,108 | - | - | -1,989 | -2,871 | 944.37 | Upgrade
|
| Change in Inventory | 984.36 | - | - | -898.05 | -144.22 | -291.43 | Upgrade
|
| Change in Accounts Payable | 1,705 | - | - | 1,499 | -169.49 | 247.2 | Upgrade
|
| Change in Unearned Revenue | 50.9 | - | - | 350.86 | 276.66 | -10.72 | Upgrade
|
| Change in Income Taxes | - | - | - | 145.98 | - | -48.16 | Upgrade
|
| Change in Other Net Operating Assets | 281.71 | 1,132 | 55.46 | -942.09 | -143.68 | -621.6 | Upgrade
|
| Operating Cash Flow | 3,347 | 4,860 | 2,190 | 1,235 | -755.68 | -1,132 | Upgrade
|
| Operating Cash Flow Growth | -31.75% | 121.86% | 77.36% | - | - | - | Upgrade
|
| Capital Expenditures | -13,898 | -5,434 | -1,361 | -6,110 | -2,326 | -1,763 | Upgrade
|
| Sale of Property, Plant & Equipment | 10.45 | 10.91 | 32.69 | 25 | - | 7.64 | Upgrade
|
| Sale (Purchase) of Intangibles | -3,157 | -1,039 | -724.77 | -632.66 | -227.92 | -397.14 | Upgrade
|
| Investment in Securities | 904.31 | -90.98 | -20.14 | 506.51 | -462.87 | 300.01 | Upgrade
|
| Other Investing Activities | -50.73 | -12 | 146.3 | 6 | -10.5 | -9 | Upgrade
|
| Investing Cash Flow | -16,191 | -6,565 | -2,773 | -6,205 | -3,027 | -1,861 | Upgrade
|
| Short-Term Debt Issued | - | 4,500 | 2,700 | 9,980 | 1,269 | 3,031 | Upgrade
|
| Long-Term Debt Issued | - | 4,000 | 2,690 | 4,378 | 2,866 | 300 | Upgrade
|
| Total Debt Issued | 31,551 | 8,500 | 5,390 | 14,358 | 4,135 | 3,331 | Upgrade
|
| Short-Term Debt Repaid | - | -3,500 | -3,200 | -10,580 | - | -1,200 | Upgrade
|
| Long-Term Debt Repaid | - | -1,101 | -1,100 | - | - | -75 | Upgrade
|
| Total Debt Repaid | -16,835 | -4,601 | -4,300 | -10,580 | - | -1,275 | Upgrade
|
| Net Debt Issued (Repaid) | 14,716 | 3,899 | 1,090 | 3,778 | 4,135 | 2,056 | Upgrade
|
| Common Dividends Paid | -375 | -312.5 | -250 | - | - | -187.5 | Upgrade
|
| Other Financing Activities | - | - | -422.07 | 378.7 | 67.73 | -225.34 | Upgrade
|
| Financing Cash Flow | 14,478 | 3,587 | 418.13 | 4,157 | 4,203 | 1,643 | Upgrade
|
| Net Cash Flow | 1,634 | 1,881 | -164.33 | -812.61 | 420.46 | -1,350 | Upgrade
|
| Free Cash Flow | -10,551 | -574.48 | 829.86 | -4,875 | -3,081 | -2,895 | Upgrade
|
| Free Cash Flow Margin | -24.96% | -1.31% | 2.05% | -15.32% | -12.45% | -17.31% | Upgrade
|
| Free Cash Flow Per Share | - | - | - | -779.93 | -493.02 | -463.15 | Upgrade
|
| Cash Interest Paid | 792.15 | 676.14 | 503.76 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 60.28 | 9.36 | 654.5 | - | - | - | Upgrade
|
| Levered Free Cash Flow | -15,942 | -3,600 | -1,412 | -5,410 | -3,594 | -2,328 | Upgrade
|
| Unlevered Free Cash Flow | -15,407 | -3,167 | -1,096 | -5,235 | -3,496 | -2,300 | Upgrade
|
| Change in Net Working Capital | -374.33 | -2,126 | 596.73 | 419.95 | 2,276 | -617.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.